SMAD3 and aneurysm-osteoarthritis syndrome: Limited data on patients with SMAD3 pathogenic variants are available at present with reports of sudden cardiac death and left ventricular hypertrophy in one of the initial series on Aneurysm Osteoarthritis Syndrome due to SMAD3 pathogenic variants (van der Linde et al., 2012).